CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Filters
11 research outputs found
Prospective Exploratory Phase II Studies of A Rotating Regime of Nilotinib and Imatinib for Frontline Treatment of Philadelphia POSITIVE (Ph+) Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL).
Author
ABRUZZESE E
ALIMENA G
+8 more
CARELLA AM
FANIN R
M. BOCCHIA
MARTINELLI G
ROSTI G
RUSSO D
SAGLIO G
SPECCHIA G AND BACCARANI M
Publication venue
Publication date
01/01/2009
Field of study
No full text
Archivio della Ricerca - Università degli Studi di Siena
Induction Intensified Regimens Including Fludarabine or Mylotarg for Acute Myeloid Leukemia Patients: Comparison by Response and Follow-up.
Author
Baccarani M
Candoni A
+10 more
Fanin R
Iacobucci I
Malagola M
Ottavini E
Paolini S
Papayannidis C
Piccaluga PP
Rondoni M
Russo D and Martinelli G.
Visani G
Publication venue
'American Society of Hematology'
Publication date
01/01/2008
Field of study
No full text
Archivio istituzionale della ricerca - Università di Brescia
Bcr-Abl Kinase Domain Mutations in Imatinib and in Second-Generation Tyrosine Kinase Inhibitor Eras: Seven Years of Mutation Analysis, a Report by the GIMEMA CML Working Party
Author
Abruzzese E
Amabile M
+18 more
and Martinelli G
Baccarani M
Breccia M
Castagnetti F
Colarossi S
Gnani A
Gugliotta G
Iacobucci I
Palandri F
Pane F
Pregno P
Rosti G
Russo D
Saglio G
Sorà F
Soverini S
Specchia G
Tiribelli M
Publication venue
Publication date
01/01/2010
Field of study
No full text
Archivio della ricerca- Università di Roma La Sapienza
A randomized study of alphaInterferon vs. alphaInterferon and low dose arabinosyl cytosine in chronic myeloid leukemia
Author
AMABILE M.
AND TURA S.
+12 more
BACCARANI M.
BONIFAZI F.
D. RUSSO
DE VIVO A.
FIACCHINI M.
MARTINELLI G.
MONTEFUSCO E.
ROSTI G.
SAGLIO G.
STUDY E WRITING COMMITTEE
TESTONI N.
THE ITALIAN COOPERATIVE STUDY GROUP ON CHRONIC MYELOID LEUKEMIA
Publication venue
American Society of Hematology:1900 M Street Northwest, Suite 200:Washington, DC 20036:(800)633-4931, (202)776-0544, EMAIL:
[email protected]
,
[email protected]
, INTERNET: http://www.hematology.org, Fax: (202)776-0551
Publication date
01/01/2002
Field of study
No full text
Archivio istituzionale della ricerca - Università di Brescia
Imatinib 800 mg: Preliminary Results of a Phase II Trial of the GIMEMA CML Working Party in Intermediate Sokal Risk Patients and Status-of-the-Art of an Ongoing Multinational, Prospective Randomized Trial of Imatinib Standard Dose (400 mg Daily) vs High Dose (800 mg Daily) in High Sokal Risk Patients
Author
Abruzzese E
Amabile M
+19 more
and Baccarani M
Bassan R
Breccia M
Castagnetti F
Haznedaroglu I
Hjorth-Hansen H
Martinelli G
Nagler A
Nielsen JL
Pane F
PorkKa K
Rosti G
Russo D
Saglio G
Simonsson B
Specchia G
Stagno F
Testoni N
Vignetti M
Publication venue
Publication date
01/01/2005
Field of study
No full text
Archivio della ricerca- Università di Roma La Sapienza
First Line Treatment with Nilotinib 800 Mg Daily Results In Unprecedentedly High Rate of Rapid, "Deep" and Stable Molecular Responses as Assessed by a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript: Results of a Phase 2 Trial of the GIMEMA CML Working Party
Author
Alimena G
Amabile M
+26 more
and Baccarani M
Bocchia M
Breccia M
Capucci A
Castagnetti F
Cedrone M
Gugliotta G
Iacobucci I
Intermesoli T
Levato L
Lonetti A
Martinelli G
Martino B
Palandri F
Pane F
Papayannidis C
Poerio A
Rosti G
Russo D
Saglio G
Soverini S
Stagno F
Terragna C
Testoni N
Tiribelli M
Zaccaria A
Publication venue
Publication date
01/01/2010
Field of study
No full text
Archivio della ricerca- Università di Roma La Sapienza
First Line Treatment with Nilotinib 800 Mg Daily Results In Unprecedentedly High Rate of Rapid, "Deep" and Stable Molecular Responses as Assessed by a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript: Results of a Phase 2 Trial of the GIMEMA CML Working Party
Author
Alimena G
Amabile M
+26 more
and Baccarani M
Bocchia M
Breccia M
Capucci A
Castagnetti F
Cedrone M
Gugliotta G
Iacobucci I
Intermesoli T
Levato L
Lonetti A
Martinelli G
Martino B
Palandri F
Pane F
Papayannidis C
Poerio A
Rosti G
Russo D
Saglio G
Soverini S
Stagno F
Terragna C
Testoni N
Tiribelli M
Zaccaria A
Publication venue
Publication date
01/01/2010
Field of study
No full text
Archivio della ricerca- Università di Roma La Sapienza
Phase II multicentric explorative study of Intermittent Imatinib (IM) treatment (INTERIM) in elderly patients with Ph+ chronic myeloid leukemia (CML) who achieved a stable complete cytogenetic response (CCgR) with standard IM therapy.
Author
Abruzzese E
Alimena G
+47 more
Amabile M
Angelucci E
Bigazzi C
Bocchia M
Bosi A
Breccia M
Colombi C
De Fabritiis P
De Vivo A and Baccarani.M
Di Lorenzo R
Di Raimondo F
Fanin R
Fioritoni G
Fogli M
Foà R
Gaidano G
Galieni P
Girasoli M
Gobbi M
Intermesoli T
Lauria F
Liso V
Lunghi M
Malagola M
Martinelli G
Martino B
Mirto S
Musolino C
Nicolini G
Nobile F
Pierri I
Pregno P
Quarta G
Rambaldi A
Rege Cambrin G
Rosti G
Russo D
Russo S
Saglio G
Santini V
Specchia G
Stagno F
Tiribelli M
Turri D
Usala E
Visani G
Vitolo U
Publication venue
'Ferrata Storti Foundation (Haematologica)'
Publication date
01/01/2009
Field of study
No full text
Archivio istituzionale della ricerca - Università di Brescia
Archivio della ricerca- Università di Roma La Sapienza
Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509
Author
Abruzzese E
Alimena G
+45 more
and Baccarani M
Annunziata M
Appolloni V
Barulli S
Breccia M
Carella AM
Castagnetti F
Cattina F
Cazzola M
Colombi C
de Fabritiis P
De Vivo A
Di Raimondo F
Durante S
Fanin R
Ferrara F
Fogli M
Gaidano G
Gobbi M
Iacobucci I
Iurlo A
Liberati AM
Longinotti M
Lunghi M
Malagola M
Martinelli G
Merante S
Musolino C
Pardini S
Pica G
Pierri I
Pregno P
Radice T
Rosti G
Russo D
Russo S
Skert C
Soverini S
Stagno S
Testoni N
Tiribelli M
Trabacchi E
Vallisa D
Visani G
Vitolo U
Publication venue
Publication date
01/01/2011
Field of study
No full text
Archivio della ricerca- Università di Roma La Sapienza
Phase II multicentric explorative study of Intermittent Imatinib (IM) treatment (INTERIM) in elderly patients with Ph+ chronic myeloid leukemia (CML) who achieved a stable complete cytogenetic response (CCgR) with standard IM therapy.
Author
Abruzzese E
Alimena G
+37 more
Amabile M
Angelucci E
Bigazzi C
Bocchia M
Bosi A
Breccia M
Colombi C
De Fabritiis P
De Vivo A and Baccarani.M
Di Raimondo F
Fanin R
Fogli M
Foà R
Galieni P
Girasoli M
Gobbi M
Intermesoli T
Lauria F
Liso V
Malagola M
Martinelli G
Mirto S
Pierri I
Pregno P
Quarta G
Rambaldi A
Rege Cambrin G
Rosti G
Russo D
Saglio G
Santini V
Specchia G
Stagno F
Tiribelli M
Turri D
Usala E
Vitolo U
Publication venue
'Ferrata Storti Foundation (Haematologica)'
Publication date
01/01/2009
Field of study
No full text
Archivio istituzionale della ricerca - Università di Brescia
1
2